Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School institutions in the Longwood Medical Area. The BIDMC faculty, together with newly recruited long-time Boston-based ECOG members now includes an exceptional group of committed clinical cancer researchers. Serving as the principal tertiary/academic resources of the CareGroup Network, BIDMC has a natural and ready-made ECOG network to add to its long tradition of excellence in cancer care as well as both clinical and basic science research. BIDMC is home to nationally recognized centers of special expertise including the Joint Center for Radiation (JCRT), liver and other solid-organ transplantation, AIDS and related malignancies, breast cancer/women's health, malignant melanoma, medical informatics and clinical trials methodology, cytokine and biologic therapy. The Harvard Institute of Medicine (H.I.M.) Located nearby provides outstanding research scientists and laboratory-based components for cooperative group translational research. BIDMC joined ECOG as an affiliate of Vanderbilt University in May 1997. From May '97-October '97, as an affiliate, BIDMC entered 36 cases. Based on this strong activity and a fully satisfactory site visit in September '97, BIDMC was granted Main Member Institution status in October '97 and approved to apply for an ECOG Core Grant in January 1998. From October '97 to December '97, as a main institution, BIDMC enrolled 19 patients to ECOG studies. To date, in 1998 BIDMC has accrued 33 patients, making the total accrual for May '97 to May '98 equal to 88 patients. We are committed to conducting laboratory and clinical research in the ECOG specified areas of cancer prevention, diagnosis, and treatment and have demonstrated high levels of patient accrual in the past and have the potential for even greater contributions, group science, and patient enrollment in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA080775-02
Application #
6173835
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1999-05-12
Project End
2004-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
2
Fiscal Year
2000
Total Cost
$149,812
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
DiPaola, Robert S; Chen, Yu-Hui; Bubley, Glenn J et al. (2015) A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 68:365-71
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53
Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B et al. (2014) Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34:376-84
Liu, Glenn; Chen, Yu-Hui; Kolesar, Jill et al. (2013) Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 31:211-8
Karp, Daniel D; Lee, Sandra J; Keller, Steven M et al. (2013) Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 31:4179-87
Liu, Glenn; Chen, Yu-Hui; Dipaola, Robert et al. (2012) Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 10:99-105

Showing the most recent 10 out of 17 publications